Skip to Content
Merck
All Photos(1)

Documents

EHU219671

Sigma-Aldrich

MISSION® esiRNA

targeting human ADRA2B

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

ATTCACCCCCTGCAAAAATCGGGGCGACAATAGCTCACTGCCTACTTGCTGCAGGGAGATGAAAGGCTTTGCAGAAAGCTTTGAGCTCTGTGGGGGAACACACTAGAGAACCAAAAATGTGATTATATGGTGATATAAAAATCCCTTTCCTCTGTGTTTACCACCACCTGTCTTCCTGTAGACTTTTGTTCTGTCCCTGGGGTGTGTGAATTCCTACCCCGAACTGGAAGCCGGGAGTGGCAGACAGAATCACTATTTCAAGTTAAAGGATCTCTTTGAGAATGTGTTCTTCTGGCTGCAAAGGTCTGAGTTATTACGCTACATGACAACGTTTCGACATTTCACCGGCAACACCAAGAGGGTTTTTAGTGGCTTGGGTCTCCCCAGTGGGGGATAAGTCTTTTGTCATCAAGGAGGCAAATTGTCTCCCCAAGACAGCTCAAAATATCCACACCTCGGCAACAGTCTAAGATGAGAGCCTGTGACAGGTGGCAGCGCCCCCAGGTGGGGTACTGGCAT

Ensembl | human accession no.

ENSG00000222040

NCBI accession no.

NM_000682

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... ADRA2B(151) , ADRA2B(151)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ina Nemet et al.
Cell, 180(5), 862-877 (2020-03-07)
Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independent cohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) and incident major adverse cardiovascular events (myocardial infarction

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service